Features of 152 families eligible for the investigation of mutations in BRCA1 / 2, evaluated Onco genetics unit Clinics Hospital

Full text: The aim of this study is to contribute to the characterization of familial breast cancer in our country. Patients and methods. We analyzed 152 families referred to the Hospital Unit Onco genetics Clinic, who had 3 or more cases of breast cancer (C M)(at least one diagnosed before age 50 years) (n = 92)or 2 cases with some sub-criterion (paternal transmission, C M bilateral C M male, ovarian cancer (O C), Ashkenazi Jewish ancestry, a case diagnosed before 40 years) (n = 47)or 4 or more cases without regard to age at diagnosis (n = 4)or an single case diagnosed before age 35 (n = 9). The clinical data collection was conducted onco genetics the query was entered in which, among others, the presence or absence of nongenetic risk factors, personal and family history of breast, ovarian and other tumors and age of diagnosis. Results. 152 cases were selected indices, carrying 148 C M (bilateral n = 29)and 4 CO. The median age at diagnosis of C M developed in these patients was 48 years (range: 25-54). Twenty-three of the 151 patients had a second tumor extra mammary (ovary n = 7; melanoma n = 2, n = 3 cervix, colon n = 4, n = 1 sarcoma, ENT = 1, = 1 pancreas, kidney = 2, CBP = 1, esophagus = 1). Among the relatives of the relevant parent branch were 329 C M (25 bilateral, 2 male)diagnosed before 50 years in more than 60 % of cases and 22 ovarian cancers. Comparing the frequency of different tumor locations both branches parents. In the relevant parent branch, and the prevalence of C M and CO documented a higher frequency of prostate, stomach, pancreas and melanoma. It was possible to obtain information He r2 tumor expression, estrogen receptor (E R) and progesterone receptor (P R) in 25 patients, finding that 10 patients (0.40)had He r2 overexpression, 11 (0.46 R E and / / or P R positive, HER2 negative and 4 E R, P R and He r2 negative (0.16). Conclusions. The characteristics of the families studied, including the frequency of tumors extramamarios agrees with the prevalence of BRCA2 mutations in familial breast cancer in our country, previously reported by our group. With respect to biological subtype although the number of patients analyzed is small, it is noteworthy the high proportion of He r2 positive patients, which justifies the study of the biological profile of a greater number of patients with a history compatible with Uruguayan hereditary predisposition